PerceptiMed’s ScripClip processes 1M scripts
Pharmacy technology company PerceptiMed has seen its will call technology ScripClip pass a big milestone. The Mountain View, Calif.-based company said Thursday that the technology, launched last year, has safely processed more than 1 million prescriptions as it expands its reach through the United States, Canada and Puerto Rico.
“Our ScripClip product provides pharmacies with a customer-facing solution for faster prescription pickups combined with improved safety,” PerceptiMed CEO Bob Curry said. “It’s the rare pharmacy automation product that pharmacy customers can actually see in operation and tells customers that their pharmacy cares about both service and their safety as a patient. We are proud of reaching this milestone in having fulfilled our millionth prescription.”
Pharmacies using the ScripClip system have avoided roughly 1,000 safety incidents, according to a pharmacy saety study, PerceptiMed said. Among the issues the system looks to eliminate are patients receiving the wrong prescriptions or incomplete prescriptions, as well as adverse reactions and HIPAA violations, all of which the company said can be costly and time-consuming.
“ScripClip pharmacies achieve quick ROIs in only six to twelve months of use,” PerceptiMed chief business officer Frank Maione said. “The financial savings are a combination of better inventory management through easy to perform return-to-stock protocols, higher customer retention rates and will call labor savings.”
CVS Health earns NCQA utilization management accreditation
CVS Health’s pharmacy benefits manager CVS Caremark has been accredited by the National Committee for Quality Assurance in utilization management.
The NCQA utilization management accreditation is earned through a quality assessment program focused on protecting consumers and improving customer service. Its standards recognize applicants with open access networks that can use customized structures to meet purchaser needs while improving service quality.
“At CVS Caremark, we are pleased to maintain our NCQA Utilization Management Accreditation, which we’ve held continuously for the past several years,” CVS Health COO Jonathan Roberts said. “This accreditation affirms that our program provides high quality service and care to our PBM clients and their members as we strive to ensure that members access clinically appropriate and cost effective therapies to help improve health outcomes and lower costs.”
CVS Caremark’s utilization management program is designed to encourage appropriate and effective medication use. The company said that it identifies optimal drug use and promotes drug benefit plans that are cost-effective by using evidence-based drug information, as well as published guidelines, consensus statements and standards of medical practice.
“Achieving utilization management accreditation from NCQA demonstrates that CVS Health has the systems, process and personnel in place to conduct utilization management in accordance with the strictest quality standards,” NCQA president Margaret O’Kane said.
The accreditation process involves an evaluation that is conducted by a team of physicians and managed care experts, whose findings are then analyzed by an independent oversight committee of physicians, which then assigns an accreditation status based on an organization’s performance against standards.
Teva Canada intros generic Concerta
Teva Canada has launched its generic Concerta (methylphenidate hydrochloride). The extended-release tablet is indicated to treat attention deficit hyperactivity disorder in patients ages 6 years and older.
“We’ve heard from healthcare providers, ADHD patients and their parents about the need for an affordable alternative to Concerta that works in the same way and at the same time,” Teva Canada senior director of commercial management David Boughner said. “We’re pleased to offer patients ACT Methylphenidate ER as a bioequivalent modified release product that allows for a biphasic drug release profile after oral administration. In addition, the pharmacokinetic parameters mimic the concentration-time release profile of Concerta.”
ADHD is the most common neurodevelopmental disorder, affecting roughly 1-in-20 children, according to Portico, Canada’s mental health and addiction network.
Teva Canada’s generic Concerta will be available in 18-, 27-, 36- and 54-mg tablets. The once-daily drug had a Canadian market size of roughly $175 million for the 12 months ended January 2018, according to IQVIA data.